Catalent Achieves Global ISO Accreditation, Becomes One of the First Contract Development and Manufacturing Organizations to Receive Award

Thursday, May 9, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that the British Standards Institute (BSI) has awarded Catalent a global accreditation against the international management standards for environment (ISO14001:2015) and Occupational Safety (OHSAS18001:2007). The accreditation, for Catalent's global Environment, Health & Safety (EHS) management system is one of the first to be awarded in the pharmaceutical industry to a contract development and manufacturing organization (CDMO).

SOMERSET, N.J., May 09, 2019 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies

and development solutions for drugs, biologics and consumer health products, today announced that the British Standards Institute (BSI) has awarded Catalent a global accreditation against the international management standards for environment (ISO14001:2015) and Occupational Safety (OHSAS18001:2007). The accreditation, for Catalent's global Environment, Health & Safety (EHS) management system is one of the first to be awarded in the pharmaceutical industry to a contract development and manufacturing organization (CDMO).

BSI's auditors judged that Catalent's EHS system demonstrates a high-degree of sophistication and maturity and competes at a world-class performance level with other leading industries and businesses.

"Our EHS system drives our core values of injury prevention and environmental sustainability, and is central to supporting customer and patient expectations," commented Mark Incledion, Catalent's Global Director, EHS. He added, "This accreditation is very much in line with Catalent's patient-first and corporate responsibility-driven philosophy, while helping us meet our environmental targets and promote a cleaner planet."

Catalent's global network of facilities produce over 70 billion doses annually and are approved by 35 regulatory agencies to provide flexible commercial and clinical manufacturing supplies in oral, sterile, biologic and inhaled dose forms for customers around the world.

About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

 

SOURCE Catalent, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store